These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29982879)

  • 1. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
    Funikov SY; Rezvykh AP; Mazin PV; Morozov AV; Maltsev AV; Chicheva MM; Vikhareva EA; Evgen'ev MB; Ustyugov AA
    Neurogenetics; 2018 Aug; 19(3):189-204. PubMed ID: 29982879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice.
    Shelkovnikova TA; Peters OM; Deykin AV; Connor-Robson N; Robinson H; Ustyugov AA; Bachurin SO; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Skvortsova VI; Ling SC; Da Cruz S; Parone PA; Buchman VL; Ninkina NN
    J Biol Chem; 2013 Aug; 288(35):25266-25274. PubMed ID: 23867462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
    Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
    Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
    Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
    Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.
    King A; Troakes C; Smith B; Nolan M; Curran O; Vance C; Shaw CE; Al-Sarraj S
    Acta Neuropathol Commun; 2015 Oct; 3():62. PubMed ID: 26452761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice.
    Lysikova EA; Funikov S; Rezvykh AP; Chaprov KD; Kukharsky MS; Ustyugov A; Deykin AV; Flyamer IM; Boyle S; Bachurin SO; Ninkina N; Buchman VL
    Neurochem Res; 2020 May; 45(5):1168-1179. PubMed ID: 32157564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
    Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
    Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristic Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic Lateral Sclerosis.
    Ikenaka K; Ishigaki S; Iguchi Y; Kawai K; Fujioka Y; Yokoi S; Abdelhamid RF; Nagano S; Mochizuki H; Katsuno M; Sobue G
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):370-377. PubMed ID: 32142134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic Lateral Sclerosis.
    Shelkovnikova TA; An H; Skelt L; Tregoning JS; Humphreys IR; Buchman VL
    Cell Rep; 2019 Dec; 29(13):4496-4508.e4. PubMed ID: 31875556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay.
    Kamelgarn M; Chen J; Kuang L; Jin H; Kasarskis EJ; Zhu H
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11904-E11913. PubMed ID: 30455313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis.
    Rademakers R; Stewart H; Dejesus-Hernandez M; Krieger C; Graff-Radford N; Fabros M; Briemberg H; Cashman N; Eisen A; Mackenzie IR
    Muscle Nerve; 2010 Aug; 42(2):170-6. PubMed ID: 20544928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis.
    Scekic-Zahirovic J; Oussini HE; Mersmann S; Drenner K; Wagner M; Sun Y; Allmeroth K; Dieterlé S; Sinniger J; Dirrig-Grosch S; René F; Dormann D; Haass C; Ludolph AC; Lagier-Tourenne C; Storkebaum E; Dupuis L
    Acta Neuropathol; 2017 Jun; 133(6):887-906. PubMed ID: 28243725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif.
    Robinson HK; Deykin AV; Bronovitsky EV; Ovchinnikov RK; Ustyugov AA; Shelkovnikova TA; Kukharsky MS; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Bachurin SO; Buchman VL; Ninkina NN
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):402-9. PubMed ID: 25991062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
    Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.
    Mitchell JC; McGoldrick P; Vance C; Hortobagyi T; Sreedharan J; Rogelj B; Tudor EL; Smith BN; Klasen C; Miller CC; Cooper JD; Greensmith L; Shaw CE
    Acta Neuropathol; 2013 Feb; 125(2):273-88. PubMed ID: 22961620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
    Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
    Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.
    Pelaez MC; Desmeules A; Gelon PA; Glasson B; Marcadet L; Rodgers A; Phaneuf D; Pozzi S; Dutchak PA; Julien JP; Sephton CF
    Acta Neuropathol Commun; 2023 Nov; 11(1):182. PubMed ID: 37974279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
    Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.
    Mackenzie IR; Ansorge O; Strong M; Bilbao J; Zinman L; Ang LC; Baker M; Stewart H; Eisen A; Rademakers R; Neumann M
    Acta Neuropathol; 2011 Jul; 122(1):87-98. PubMed ID: 21604077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.